FDA enforcement, a wrongful-death suit, and an expiring telehealth rule are converging on a ketamine industry that scaled far faster than its safeguards.
Key Takeaways
- One approved product, a vast off-label market: Only esketamine (Spravato) is FDA-approved for depression, and it is locked behind a REMS that requires in-clinic dosing and monitoring. Everything else, from infusion clinics to mail-order troches, is off-label.
- Enforcement is arriving on three fronts at once: The FDA is issuing warning letters to compounded-ketamine sellers, a venture-backed telehealth provider faces a wrongful-death suit, and the DEA telehealth flexibility expires December 31, 2026. The regulatory scaffolding the boom skipped is being built after the fact.
- The business model is the risk: At-home telehealth ketamine rests on a video intake, a compounding pharmacy, and a shipping label, with monitoring that is often minimal. That structure is exactly what regulators and plaintiffs are now testing.
- The shakeout will favor the supervised model: Providers with real clinical oversight, in-person evaluation pathways, and defensible documentation are positioned to survive. The mail-order model built on a regulatory loophole is the most exposed.
The pitch was irresistible, and that was the problem. Ketamine, a battlefield anesthetic in use since the 1970s, turned out to lift the symptoms of severe depression within hours rather than the weeks that conventional antidepressants demand, and for patients who had failed every other treatment, the effect could feel like a reprieve.
Around that clinical promise, an industry assembled with remarkable speed: infusion clinics in strip malls, wellness-branded storefronts, and, once the pandemic loosened the rules on prescribing controlled substances over video, a wave of telehealth companies that would mail a patient compounded ketamine to take at home, alone, after a brief consultation on a screen.
The treatment was legitimate, but the scaffolding around it, in large parts of the market, was not. That gap is now closing, and 2026 is the year it closes hard. A wrongful-death lawsuit, a run of federal warning letters, and the looming expiration of the emergency rule that made mail-order ketamine possible are converging on an industry that scaled faster than its own safety protocols.
For behavioral health operators and the investors circling this space, the ketamine story has become a case study in what happens when a powerful drug, a genuine clinical need, and a regulatory loophole meet, and in what the reckoning looks like when the loophole starts to close.
One FDA-Approved Ketamine Product, and a Market of Exceptions
The single most important fact about ketamine as an industry is also the least understood by the patients who use it: ketamine is not approved by the Food and Drug Administration to treat any psychiatric condition. It is approved as an anesthetic. Every use of it for depression, anxiety, or post-traumatic stress, whether delivered by infusion in a clinic or mailed as a lozenge, is off-label, which is legal but unstandardized, leaving dosing, screening, and monitoring to vary from one provider to the next.
There is exactly one exception, and its shape explains the entire regulatory fault line. Esketamine, a molecule derived from ketamine and sold as the nasal spray Spravato, is FDA-approved for treatment-resistant depression, and in 2025 the agency cleared it for use on its own rather than only alongside an oral antidepressant.
But approval came wrapped in one of the strictest safety regimes the agency maintains, a Risk Evaluation and Mitigation Strategy, or REMS, requiring that the drug be administered only in a certified health care setting with the patient monitored for at least two hours afterward. That contrast is the whole story. The one approved version is bolted to in-person supervision; the sprawling off-label market beside it, the telehealth corner above all, was built specifically to avoid that friction.
How Telehealth Turned Ketamine Into a Mail-Order Product
Telehealth ketamine exists because of a regulatory accident. When the pandemic hit, federal regulators waived the longstanding requirement that a controlled substance be prescribed only after an in-person examination, and a category of company rushed through the opening: a patient fills out an online questionnaire, meets briefly with a clinician over video, and is mailed compounded ketamine troches to dissolve at home. Compounding pharmacies are permitted to prepare ketamine because the drug itself is approved, which lets these companies bypass the FDA’s usual approval process entirely while still shipping a powerful dissociative anesthetic to people’s homes.
Its scale is not trivial. Mindbloom, the largest of the telehealth ketamine providers, operates in 38 states and says it has guided hundreds of thousands of at-home dosing sessions since 2019, and the broader market has been estimated to run into the billions, with roughly half of it flowing through telehealth and off-label prescribing rather than supervised clinics. What is missing from much of that volume is the monitoring the REMS demands for the one approved product. In the telehealth model, supervision is frequently automated or reduced to a video check on the first session, which means a great many people are taking a drug known for sedation, dissociation, and abuse potential with no clinician present, a decentralized experiment running in bedrooms across the country.
The Enforcement Reckoning Arrives on Three Fronts
For years, the safety concerns stayed largely theoretical in the eyes of regulators. In 2026 they became concrete, on three fronts at once. Start with the courts. Mindbloom is facing a wrongful-death lawsuit filed in North Carolina over the death of a 27-year-old patient who died of ketamine toxicity with hypertension after, the suit alleges, the company shipped him ketamine despite a documented history of high blood pressure, elevated heart rate, and substance use, and despite his missing multiple appointments. The case puts the telehealth model’s core weakness, screening and monitoring conducted at arm’s length, directly in front of a jury.
The FDA is the second front. In June 2026 the agency issued warning letters to online ketamine sellers, targeting the marketing and distribution of compounded and unapproved ketamine products, part of a broader enforcement pattern it had already established against compounded GLP-1 weight-loss drugs. That playbook, regulator pressure paired with manufacturer litigation, is well suited to any market built on compounded alternatives to an approved drug, and ketamine fits the template closely. The FDA has warned since 2023 about the risks of compounded oral ketamine, and the 2026 letters signal the warnings now come with enforcement behind them.
The calendar is the third. The pandemic-era flexibility that let providers prescribe controlled substances over video without an in-person visit has been extended repeatedly, and the current extension runs only through December 31, 2026. For a company whose entire model depends on remote prescribing, the expiration is an existential variable. If the permanent rule that eventually replaces it requires in-person evaluation for controlled substances, the mail-order ketamine business as currently built becomes difficult to operate, a dependence on regulatory continuity that no quantity of growth capital can hedge.
Why the Clinical Evidence Complicates the Business
Underneath the regulatory questions sits a clinical one that the industry’s marketing tends to smooth over. Ketamine’s antidepressant effect, though real and sometimes dramatic, is often short-lived, which is what pushes patients toward the repeated dosing that sustains the business model and, at the same time, raises the risks that come with sustained use, including bladder damage, dependence, and the dissociative experiences that can go wrong without supervision. Its evidence base is strong enough to justify careful clinical use and thin enough that aggressive direct-to-consumer marketing outruns it, a tension familiar from other corners of behavioral health where demand and enthusiasm have moved ahead of the reimbursement and evidence.
This is the uncomfortable middle the responsible operators occupy. Ketamine is not snake oil; for treatment-resistant depression and acute suicidality it is one of the few truly rapid tools psychiatry has, and dismissing it wholesale would abandon patients who benefit. But it is also not a wellness supplement to be shipped on a subscription, and the companies that blurred that line invited exactly the scrutiny now arriving. The clinical reality and the business incentives point in different directions, and the gap between them is where the harm has accumulated.
What the Ketamine Shakeout Means for Operators
For providers and investors, the strategic read is that the ketamine market is not collapsing but consolidating around whoever can operate it safely and defend that operation on paper. Clinics and platforms most likely to survive are the ones that already look least like the loophole: real psychiatric intake, meaningful in-person evaluation or a compliant pathway to it, monitoring that matches the drug’s risk profile, marketing that stays inside what the evidence supports, and documentation that could withstand a plaintiff’s attorney or an FDA reviewer. Those safeguards cost money and slow growth, which is precisely why so much of the market skipped them, and precisely why the market is now being forced to rebuild them.
Investment history hints at how this resolves. Ketamine providers have struggled to attract traditional private-equity capital in part because of exactly the headline risk the Mindbloom case embodies, the same discomfort that makes buyers wary of seriously-mentally-ill and inpatient psychiatric assets more broadly. A wrongful-death verdict, or a permanent telehealth rule that requires in-person care, could set the industry’s push for legitimacy back years. Or the shakeout could do the field a favor, clearing out the operators who treated a dissociative anesthetic like a consumer product and leaving the ones building something that deserves to be called treatment.
Which of those happens depends less on the drug, whose clinical value is not really in dispute, than on whether the surviving businesses can make peace with the supervision the safe version of this always required. The loophole is closing. What gets built in its place is the actual question.
